Hosted on MSN2mon
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
It builds on the success of Trikafta by covering all mutations included in its label, along with an additional 31 CF-causing mutations. Trikafta was initially approved in 2019 for patients aged 12 ...
The Scientist5y
FDA Approves New Cystic Fibrosis Drug
Trikafta, made by Vertex Pharmaceuticals, is, as its name suggests, a combination of three drugs. It works for 90 percent of patients with cystic fibrosis, and will be priced at $311,000 per year.